Sanofi acquires immune and inflammatory disease specialist Kymab
Sanofi has acquired Kymab, a clinical-stage biopharmaceutical company based in Cambridge, developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology...
Merger Agreement for Astellas Pharma Inc and iota Biosciences
Astellas Pharma Inc. and iota Biosciences, Inc. have announced that Astellas, through a U.S. subsidiary, and iota have entered into a Merger Agreement, with...
Merger announced between RBW Consulting and Thorp Associates, with new Chief Growth Officer
A merger has been announced between RBW Consulting, specialist life science and technology search consultancy, and Thorp Associates, executive search and selection company. Emma Thorp,...
AbbVie to acquire Allergan in “transformative move”
Abbvie to acquire Allergan after entering into a definitive transaction agreement under which AbbVie will acquire the company in a cash and stock transaction...
Novartis acquires IFM Tre
Novartis will add to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC focused...
GHO Capital acquires Sterling Pharma Solutions
European specialist investor in healthcare, GHO Capital, has acquired a majority stake in Sterling Pharma Solutions, a specialist in complex and difficult to manufacture...
Healthtech M&A and IPO Activity
The latest Healthtech M&A and IPO Activity Market Report from Hampleton Partners has revealed a final count of almost 100 deals in the healthtech...
DoseCare acquires Biodose
DoseCare announces its acquisition of Biodose, the UK’s only monitored dosage system (MDS) that accommodates liquid and solid medication. Biodose, a medication management solution,...
UK pharma pressing ahead with M&As in 2019
The UK pharmaceutical industry is pressing ahead with M&A activity and is geared to weather any disruption due to Brexit, according to the results...
Sanofi and Denali join forces on inflammatory disease drugs
Sanofi plans to collaborate with Denali Therapeutics Inc. on the development of multiple molecules with the potential to be neurological and systemic inflammatory disease...